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Performance and operational characteristics of 
point-of-care tests for the diagnosis of urogenital 
gonococcal infections
Rebecca J Guy,1 Louise M Causer,1 Jeffrey D Klausner,2 Magnus Unemo,3 Igor Toskin,4 
Anna M Azzini,5 Rosanna W Peeling6
AbstrAct
background In 2012, there was an estimated 
78 million new cases of gonorrhoea globally. Untreated 
infection may lead to reproductive and neonatal 
morbidity and facilitate HIV transmission. Diagnosis 
and treatment are a priority for control and prevention, 
yet use of point-of-care tests (POCTs) for Neisseria 
gonorrhoeae (NG) is limited.
Objectives To review the performance and operational 
characteristics of NG POCTs for diagnosis of urogenital 
gonorrhoea.
Methods We compiled and synthesised findings 
from two separate systematic reviews which included 
evaluations published until August 2015.
results Six tests were included: five were 
immunochromatographic tests (ICTs) or optical 
immunoassay (OIAs) based on antigen detection; 
with 5–7 steps and results in 25–40 min, and one 
(GeneXpert CT/NG) was a ’near-patient test’ based 
on nucleic acid amplification technique (NAAT); with 
three steps, electricity required, and results in 90 min. 
When compared with laboratory-based NAATs as the 
reference tests, sensitivities of ICT and OIA-based POCTs 
ranged from 12.5% to 70% when cervical/vaginal swabs 
were tested. Specificities ranged from 89% to 99.8%. 
The near-patient NAAT had sensitivities of >95% and 
specificities of >99.8% consistently across all specimen 
types (urine, cervical and vaginal swabs).
conclusions Based on a limited number of evaluations, 
antigen detection POCTs for NG lacked sufficient 
sensitivity to be used for screening. A near-patient 
NAAT has acceptable performance, only involved a few 
steps, but needs electricity, a temperature-controlled 
environment and has a 90 min run time. To achieve 
wider scale up of NG POCTs, we need strong evidence 
of cost-effectiveness, which should inform guidelines 
and ultimately increase test development, demand and 
reduce costs.
IntrOductIOn
Gonococcal infection (or gonorrhoea), caused by the 
bacterium Neisseria gonorrhoeae (NG), is a curable 
STI. In 2012, WHO estimated that 78 million new 
cases of gonorrhoea occurred globally.1 Uncom-
plicated gonorrhoea is characterised by abnormal 
vaginal discharge, bleeding and dysuria in women, 
and may result in urethral discharge and dysuria in 
men.2 3 Infections of the rectum and pharynx, which 
are mostly asymptomatic, can occur in both sexes.4 
The majority of urogenital infections in women are 
asymptomatic; and in men approximately half of 
infections can be asymptomatic.2 5 Untreated infec-
tion can lead to serious reproductive complications 
such as pelvic inflammatory disease, infertility and 
ectopic pregnancy in women and epididymo-orchitis 
in men.4 Untreated infection in pregnancy may lead 
to preterm birth.6 Babies born to infected mothers 
may develop ophthalmia neonatorum, resulting in 
blindness.7 Gonorrhoea has been associated with an 
increased risk of acquiring and transmitting HIV,8 
including perinatal transmission.9 The mainstay for 
control of gonorrhoea is effective diagnostics and 
subsequent antimicrobial treatment; however, due 
to widespread antimicrobial resistance, therapeutic 
options have become very limited in recent years.10 
Accordingly, dual antimicrobial therapy (mostly 
ceftriaxone plus azithromycin) has been introduced 
in well-resourced settings.11 Diagnostic tests of high 
performance are key for early detection to guide 
treatment to prevent the development of sequelae 
and adverse pregnancy outcomes and interrupt 
onward transmission.
Traditionally, culture of NG was the gold 
standard for diagnosis. However, with the devel-
opment of highly sensitive and specific nucleic acid 
amplification technologies (NAATs) in the past 
decade, which are both more forgiving in terms 
of specimen collection and transport than culture 
techniques and are highly automated, these assays 
are now the diagnostic of choice across laborato-
ries in more-resourced settings.12 In low-and-mid-
dle-income countries (LMICs), such laboratory 
services are either not available, or where limited 
services are available, patients many not be able to 
pay for or physically access these services. In these 
settings, syndromic management is widely imple-
mented. Unfortunately, this approach does not 
work well for some syndromes, particularly the 
syndrome of vaginal discharge and fails to identify 
those with asymptomatic infection, leaving a large 
untreated population pool at risk of complications 
and ongoing transmission.13 Syndromic-guided 
management thus represents a clinical approach 
that can enhance presumptive, inappropriate antibi-
otic treatment of symptomatic subjects, potentially 
increasing the risk of antimicrobial resistance devel-
opment, which represents an urgent challenge for 
NG in this age of ‘antibiotic stewardship’.10
Globally, the development and application of 
point-of-care tests (POCTs) for curable STIs is 
recognised as an important approach to overcome 
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the barriers to access and timeliness of diagnosis, a key priority in 
the control of curable STIs. According to the ASSURED criteria, 
POCTs should be affordable, sensitive, specific, user-friendly, 
rapid and robust, equipment-free and deliverable.14 However, 
others have broadened this framework to include any diagnostic 
tool that can provide accurate results and facilitate treatment 
within the same clinical visit as testing, a definition that includes 
some NAATs that do not fit the classic ASSURED criteria.15 
Simple rapid POCTs for the diagnosis of gonorrhoea are 
commercially available; however, these POCTs have tradition-
ally suffered from low sensitivity. Emerging new technologies, 
including amplification technologies, promise major advances 
in the field of rapid POCTs for NG in the near future. The 
WHO STI POC Diagnostic Initiative has been coordinated by 
the Department of Reproductive Health and Research at WHO, 
including the UNDP/UNFPA/Unicef/WHO/World Bank Special 
programme of research, development and research training in 
human reproduction (http://www. who. int/ reproductivehealth/ 
topics/ rtis/ pocts/ en/). The need to accelerate development and 
thereby access to NG POCTs and testing, particularly in LMIC, 
have been emphasised in the Global Health Sector Strategy on 
STIs that was endorsed at the 69th World Health Assembly in 
May 2016.16
Two recent comprehensive systematic reviews of POCTs for 
urogenital gonorrhoea have been published covering consecutive 
time periods up to August 2015: the first by Watchirs-Smith et al 
in 20 0117 and the second by Herbst de Cortina et al in 2016.18 
This paper synthesises the findings reported in these reviews as 
they relate to the performance and operational characteristics 
of commercially available POCTs for the diagnosis of urogenital 
NG infection.
MethOds
Both systematic reviews were conducted according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement.19
systematic review 1
The first review by Watchirs-Smith et al17 searched both PubMed 
and Embase using a comprehensive search term including ‘rapid 
test’, or ‘POC test’, or ‘POCT’ or ‘LE’ or ‘urine dipstick’, AND 
‘gonococcal’, or ‘gonorrhoea’, or ‘N gonorrhoeae’ AND ‘evalu-
ation’ or ‘performance characteristics’ or ‘validation’ or ‘perfor-
mance’ or ‘sensitivity’ or ‘specificity’. The search was limited to 
English-language publications and to the period prior to August 
2010. The authors defined rapid POC testing as any system that 
provided rapid gonorrhoea diagnosis results at the point of care 
and could be conducted with minimal operator skill and infra-
structure. The identified papers were reviewed and information 
was extracted by two authors independently. Disagreements 
were resolved by discussion and consensus. Papers were included 
if the reference standard for comparison was laboratory-based 
NAAT or bacterial culture. Papers were excluded if the test was 
conducted on clinical isolates rather than field samples or if the 
paper did not report primary data or only described the applica-
tion and did not report on performance of the test.
systematic review 2
The second review by Herbst de Cortina et al18 also used a 
comprehensive search term of a compilation of medical subject 
headings, text words and subheadings to search PubMed (sexu-
ally transmitted diseases or sexually transmitted infection* and 
(chlamydia or gonorrh* or trichom*)) and (point-of-care and 
(rapid test or diagnostic or screening or test)). The search was 
limited to English-language publications and included the period 
of January 2010 to August 2015. The authors had a broader 
scope for their review and were interested in a search that 
included publications relating to diagnostic performance, cost 
analyses, acceptability and proof-of-concept studies and also, 
in addition to NG, they included Chlamydia trachomatis (CT) 
and Trichomonas vaginalis (TV). Exclusion criteria included 
those papers reporting on these infections but not in the sexually 
transmissible form as stated by the review authors.
For all papers meeting the inclusion criteria, information was 
extracted on the setting, participants (age, sex, genital symp-
toms), evaluation design (sample size, specimen type), POCT 
(type, manufacturer, brand name), gold standard reference test 
(NAAT, culture or microscopy), POCT performance (sensitivity, 
specificity, positive predictive value (PPV) and negative predic-
tive value (NPV)) and for the first review, operational character-
istics (number of steps, major equipment, time to result).
Although microscopy can be used to complement syndromic 
management at the point of care, in particular to exclude gono-
coccal urethritis in men, this method was not included in our 
present review as its focus is near-patient antigen or DNA detec-
tion techniques.
results
The literature search conducted by Watchirs-Smith et al17 iden-
tified 100 papers in total, including 14 in their published review 
paper: 9 were on leucocyte esterase (LE) dipsticks, 2 were on 
microscopy and 3 were on POCT for NG. The systematic review 
literature search by Herbst de Cortina et al18 identified 61 papers 
in total, 33 of which were included in the qualitative synthesis 
reported in their paper: 4 of these related to detection of NG 
(3 were POCT and 1 was traditional Gram stain microscopy) 
(table 1). For this overview, the papers related to evaluations 
of LE dipsticks and microscopy were excluded as they did not 
detect NG specifically (n=12).
Based on these two recent comprehensive systematic 
reviews,17 18 a total of six studies were identified from the 
published literature prior to August 2015 reporting on the 
performance of six diagnostic tests designed to detect NG and 
suitable for use at the POC. Table 2 summarises the extracted 
data from these studies. The POCTs evaluated included the 
GC Check (PATH, Seattle, Washington, USA),20 BioStar (GC 
OIA) (ThermoFisher/BioStar, Boulder, Colorado, USA),21 22 
Binax NOW Gonorrhoea Test (Inverness),23 GeneXpert CT/
NG (Cepheid, Sunnyvale, California, USA),24 ACON Duo25 and 
NG ACON Plate (ACON NG) (ACON Laboratories, San Diego, 
California, USA).25 The ACON Duo, NG ACON, GC Check 
and Binax NOW are lateral flow immunochromatographic tests 
(ICTs); the BioStar is an optical immunoassay (OIA) tests; the 
GeneXpert CT/NG assay is based on NAAT (this test is referred 
to as a ‘near-patient NAAT’ hereafter because of the longer time 
to results than traditional POCTs). Two tests (GeneXpert and 
Acon Duo) are designed to detect presence of both NG and CT 
simultaneously from the same patient sample; however, only the 
results for the NG component are included here. The GeneX-
pert is also the only test designed to detect two highly conserved, 
non-chromosomal NG targets that are unique to NG and not 
found in other Neisseria species.
Most tests were each only evaluated in one study, although 
one OIA (Biostar OIA) was evaluated in two studies.21 22 Evalua-
tions were conducted in 5958 patients across a range of settings 
(public and sexual health clinics, family planning and obstetrics/
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gynaecology (OBGYN) clinics and a urology department) and 
in six countries (the USA, the UK, Benin, Brazil, Columbia and 
Japan). The percentage of symptomatic clients in the study 
population ranged from 5.4% to 100%; however, most study 
populations were largely drawn from symptomatic clients.
Most tests were compared with laboratory-based NAATs as 
the reference standard, while two were compared with culture 
alone; one was compared with laboratory-based NAAT, culture 
and microscopy as reference tests and reported independently. 
The near-patient NAAT evaluation included testing a compre-
hensive selection of specimens: urine from men and endocervical 
swab, vaginal swab and urine from women.24 Other evaluations 
included either men (urine) or women (cervical and/or vaginal 
swab) only.
Operational characteristics
The near-patient NAAT required three steps to perform, 
required electricity for operation and a temperature-controlled 
environment, with an objective result in an electronic format 
available in 90 min. In contrast, the ICTs and OIAs required 
nearly twice as many steps (5–7 steps) to perform, had a shorter 
time to result (25–40 min) and no power supply was required 
to perform the test. However, the ICTs and OIAs require good 
lighting and good vision on the part of the operator as subjec-
tive visual interpretation of the presence or absence of a control 
and test line is required to determine the result and there is no 
permanent record.
Performance
The near-patient NAAT had the highest sensitivities (>95%), 
with almost 100% specificities, consistently across all specimen 
types and both sexes.24 When compared with laboratory-based 
NAATs as the reference tests, among the ICTs and OIAs, sensi-
tivities ranged from 12.5% with the ACON Duo test25 to 
100% with the BioStar test; however, this study only included 
5 NG-positive men (of 52 men in total).22 Figure 1 highlights 
the range of sensitivities and CIs of those POCTs. Specificities 
ranged from 89% to 99.8% for the ICTs and OIAs tests. One test 
(Binax Now) was evaluated among urine of symptomatic men 
and only compared with culture, no longer the accepted gold 
standard reference comparison.23
Four POCTs (compared with laboratory-based NAATs) were 
evaluated using cervical swabs; GeneXpert CT/NG (sensi-
tivity=100%, specificity=100%), GC check (sensitivity=70%, 
specificity=97%), BioStar OIA GC (sensitivity=60%, 
specificity=89%), ACON NG Duo (sensitivity=12.5%, 
specificity=99.8%) and two using vaginal swabs; GeneXpert 
(sensitivity=100%, specificity=99.9%) and GC check (sensi-
tivity=54%, specificity=98%). Only the GeneXpert CT/NG 
and BioStar OIA were evaluated using urine; with a sensitivity 
of 95.6% (females) and 98.0% (males) and specificity of 99.9% 
(males and females) for GeneXpert CT/NG; and sensitivity of 
100% and specificity of 90% for BioStar, respectively (table 3).
dIscussIOn
This synthesis of two comprehensive systematic reviews included 
only six published papers relating to POCTs for NG, reporting 
on a total of six tests: four ICTs, one OIA and one near-patient 
NAAT-based test. Most studies were conducted in highly symp-
tomatic key populations and among either men or women, not 
both. All but two evaluations21 23 were compared with laborato-
ry-based reference NAATs, the current gold standard reference 
diagnostic test. The sensitivities of the ICTs/OIAs varied from 
12.5% to 100% and specificities were >97%. As highlighted in 
table 3, some of the studies had small sample sizes and small 
numbers of gonococcal infections, resulting in large CIs around 
the point estimates of sensitivity and specificity.22 25 All ICTs/
OIAs required five or more steps to perform the test and took 
between 25 and 40 min for a result, excluding any specimen 
preparation time. By contrast the near-patient NAAT had very 
high sensitivities (>95%) and specificities (>99.9%) across spec-
imen type and gender, required three steps to perform the test, 
minimal specimen preparation with results available in 90 min.
Until recently, commercially available POCTs for NG were 
mainly single antigen detection, as either a lateral flow ICT strip 
or OIA. As shown in this review, the majority of these tests had 
unacceptable sensitivity and required significant number of steps 
to perform and subjective visual interpretation, limiting their 
user-friendliness and compliance with the ASSURED criteria. Of 
the two ICTs reported, both (GC Check1 and the NOW GC3) 
are no longer commercially available. As shown in the review, 
most evaluations of ICT or OIA NG POCTs were conducted 
using cervical or vaginal swabs, despite urine being a commonly 
collected sample, particularly for screening. In a field study by 
Causer et al26 not included in these two systematic reviews, 
another NG ICT (Gonorrhea Card Test, Immuno-Diagnostics, 
Foster City, California, USA) was evaluated using urines collected 
through community screening (men and women, n=29), with a 
sensitivity 66.7% (12.5–98.2). Although the time to results was 
15 min, combined with specimen preparation which required 
centrifugation as routinely collected urine specimens were used, 
the total time to result from time of collection was ~33 min. 
table 1 Comparison of two published systematic reviews regarding point-of-care tests (POCTs) for detection of Neisseria gonorrhoeae
review #1
(Watchirs-smith et al)17
review #2
(herbst de cortina et al)18
Focus POCTs for NG (operational characteristics and performance) POCT diagnostics for NG, CT, TV (performance, cost analyses acceptability 
and feasibility trials, proof of concept)
Language English only English only
Time Prior to August 2010 January 2010 to August 2015
Search PubMed, Embase PubMed
Search terms ‘rapid test’, or ‘POC test’, or ‘POCT’ or ‘LE’ or ‘urine dipstick’, AND 
‘Gonococcal’, or ‘gonorrhoea’, or ‘N gonorrhoeae’ AND ‘evaluation’ 
or ‘performance characteristics’ or ‘validation’ or ‘performance’ or 
‘sensitivity’ or ‘specificity’
Sexually transmitted diseases or sexually transmitted infection* and 
(chlamydia or gonorrh* or trichom*)) and (point-of-care and (rapid test or 
diagnostic or screening or test))
Papers: yield/included 100/14 61/33
Papers with NG focus 14 4
CT, Chlamydia trachomatis; NG, Neisseria gonorrhoeae; TV, Trichomonas vaginalis.
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For POCTs based on single antigen detection to be able to be 
used routinely, two major enhancements are needed: (1) further 
developmental research to increase their sensitivity and (2) 
modification to processes to reduce the number of steps.
Recent technological advances have resulted in the develop-
ment of new NAAT-based assays with performance characteris-
tics similar to those of the reference laboratory NAATs. Recent 
field testing of this CT/NG assay in remote primary health 
services in Australia has demonstrated its feasibility and high 
operational performance in a clinical primary care setting.26 27 
Pilot studies have also been conducted in antenatal settings in 
Papua New Guinea and Botswana with the GeneXpert CT/NG 
test integrated into the antenatal pathway, with nearly all women 
agreeing to be tested, and for those who were positive, all were 
treated; 80%–100% of them on the same day, despite the 90 min 
wait for results.13 28 Although the electricity requirement for the 
GeneXpert CT/NG assay may limit its use for some communi-
ty-based screening and immediate treatment, the assay could still 
improve access to and delivery of more timely results as speci-
mens can be easily collected and transported for testing to the 
nearest suitable location with a source of electricity to power 
the test. Furthermore, this limitation related to power supply 
should be overcome by the new portable, battery-powered 
GeneXpert Omni device. A further advantage of the GeneXpert 
test not addressed at all with ICTs is the incorporation of two 
NG targets, minimising the chance of false positive results with a 
commensal Neisseria species. This essentially equates to a ‘screen 
and confirm’ approach as would be routine practice in a labo-
ratory setting. Also the GeneXpert is a dual test, which incor-
porates a simultaneous CT detection assay within the same test 
cartridge.26 Very little data are available regarding the perfor-
mance of any NG POCT for use with extragenital samples.
A number of novel rapid POC molecular platforms for detec-
tion of NG and CT are in the pipeline, which might become 
exceedingly valuable. However, due to the increasing antimicro-
bial resistance in NG, a POCT that provides a diagnostic result 
simultaneously with antibiotic resistance information would be 
ideal. The feasibility and accuracy of NAATs to determine anti-
microbial resistance has been reported recently.29 Such a test 
would provide LMICs with antimicrobial resistance data which 
had previously been limited and also enable individualised treat-
ment, allowing recycling of antibiotics such as ciprofloxacin in 
areas where ceftriaxone treatment is recommended.30
In summary, prior to August 2015, there have been very few 
published evaluations of POCTs for NG. Among the six iden-
tified, the majority demonstrated sensitivities and specificities 
too low to support routine use for screening and case finding. 
The new NAAT-based near-patient test had acceptable perfor-
mance to be used for routine testing, and also with fewer steps 
to perform a test. From the pilot field studies in a number of 
Figure 1 Comparison of sensitivities of Neisseria gonorrhoeae point-of-care tests compared with nucleic acid amplification technologies. CS, endo/
cervical swab; F, female; M, male; U, urine; VS, vaginal swab.
table 3 Sensitivities and specificities of Neisseria gonorrhoeae point-of-care tests compared with nucleic acid amplification technologi (NAAT) by 
specimen type
specimen test number
Positive 
nAAt
sensitivity
(%) 95% cI negative nAAt specificity (%) 95% cI
Urine
  Male GeneXpert CT/NG 1387 50 98.0 88.4 to 99.9 1336 99.9 99.6 to 100
BioStar 52 5 100 57 to 100 47 98 98 to 100
  Female GeneXpert 1722 23 95.6 78.1 to 99.9 1695 99.9 99.7 to 100
Swab
  Cervical GeneXpert CT/NG 1722 22 100 87.3 to 100 1688 100 99.8 to 100
GC check 1084 50 70 55 to 82 1034 97 96 to 98
ACON NG Duo 491 8 12.5 0 to 41.7 483 99.8 99.3 to 100
  Vaginal GeneXpert CT/NG 1722 22 100 87.3 to 100 1691 99.9 99.6 to 100
GC check 1084 50 54 37 to 71 1034 98 97 to 99
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settings, acceptability of the NAAT-based test is high, but further 
implementation research is warranted. We did not compare 
the cost of the assays as some POCTs are no longer commer-
cially available and for others the market price for LMICs is not 
known. To truly increase uptake of NG POCTs to reduce disease 
burden worldwide, we need strong evidence of cost-effective-
ness in LMICs to invest in POC testing, which should inform 
guidelines and ultimately stimulate development of new tests, 
increase demand and thereby reduce costs.
Key messages
 ► Neisseria gonorrhoeae point-of-care tests based on antigen 
detection lack sensitivity for screening, require 5–7 steps and 
results are available in 25–40 min.
 ► Near-patient nucleic acid amplification technologies have 
acceptable performance with fewer steps, but need electricity 
and have a turnaround time of 90 min.
 ► Strong evidence of cost-effectiveness is needed to inform 
guidelines and increase investment in test development, 
demand and reduce costs.
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